Teneligliptin - Mitsubishi Tanabe Pharma Corporation

Drug Profile

Teneligliptin - Mitsubishi Tanabe Pharma Corporation

Alternative Names: MP-513; Tenelia; teneligliptin hydrobromide hydrate

Latest Information Update: 08 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Handok Inc; Mitsubishi Tanabe Pharma Corporation
  • Class Antihyperglycaemics; Ketones; Piperazines; Pyrazoles; Thiazolidines
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 01 Apr 2018 Mitsubishi Tanabe Pharma initiates a phase II trial in Type-2 diabetes mellitus (Combination therapy) in Japan (PO) (UMIN000030043)
  • 21 Feb 2018 Phase I development is ongoing in USA (PO) (Mitsubishi Tanabe pipeline, February 2018)
  • 05 Jan 2018 National Cerebral and Cardiovascular Center initiates enrolment in a clinical trial for Type-2 diabetes mellitus (In adults, In the elderly) in Japan (UMIN000030343)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top